Published Online
on August 17, 2009

A more recent version of this article appeared on October 1, 2009

This Article Full Text (PDF) All Versions of this Article: 54/4/710    most recent HYPERTENSIONAHA.109.138883v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Rossi, G. P. PubMed PubMed Citation Articles by Rossi, G. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LOSARTAN POTASSIUM PROSTAGLANDIN F2ALPHA Medline Plus Health Information Metabolic Syndrome Related Collections Risk Factors Other hypertension Glucose intolerance Clinical Studies Other Treatment Mechanism of atherosclerosis/growth factors Related Article

Losartan Metabolite EXP3179. An AT1-Receptor–Independent Treatment Strategy for Patients With the Metabolic Syndrome?

Gian Paolo Rossi^*

From the DMCS – Internal Medicine 4, University of Padua, Italy.

^* To whom correspondence should be addressed. E-mail: gianpaolo.rossi{at}unipd.it.

Related Article:

Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR Activation

Kai Kappert, Oleg Tsuprykov, Jan Kaufmann, Jan Fritzsche, Ingo Ott, Matthias Goebel, Ilse Nirmala Bähr, Paul-Laszlo Häßle, Ronald Gust, Eckart Fleck, Thomas Unger, Philipp Stawowy, and Ulrich Kintscher
Hypertension 2009 54: 738-743. [Abstract] [Full Text] [PDF]